Product Name :
Mavacamten
Description:
Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
CAS:
1642288-47-8
Molecular Weight:
273.33
Formula:
C15H19N3O2
Chemical Name:
6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
Smiles :
CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)C1C=CC=CC=1
InChiKey:
RLCLASQCAPXVLM-NSHDSACASA-N
InChi :
InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.|Product information|CAS Number: 1642288-47-8|Molecular Weight: 273.33|Formula: C15H19N3O2|Chemical Name: 6-{[(1S)-1-phenylethyl]amino}-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione|Smiles: CC(C)N1C(=O)NC(=CC1=O)N[C@@H](C)C1C=CC=CC=1|InChiKey: RLCLASQCAPXVLM-NSHDSACASA-N|InChi: InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 83.33 mg/mL (304.87 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Aliskiren hemifumarate} site|{Aliskiren hemifumarate} Renin|{Aliskiren hemifumarate} Biological Activity|{Aliskiren hemifumarate} In Vivo|{Aliskiren hemifumarate} manufacturer|{Aliskiren hemifumarate} Autophagy} |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Mavacamten is found to have an IC50 value of 490 nM in the bovine system, 711 nM in the human system, and 2140 nM in the rabbit system, indicating selectivity of >4-fold for cardiac myosin.{{NPB} web|{NPB} Bcl-2 Family|{NPB} Purity & Documentation|{NPB} Data Sheet|{NPB} custom synthesis|{NPB} Epigenetics} |In Vivo:|Treatment with Mavacamten reduces FS from 52±3% to 38±7%.PMID:23618405 Treatment with Mavacamten reduces FS from 81±7% to 60±13%, corresponding to a relative reduction of 25%. Across all measurements there is a linear correlation between FS and Mavacamten plasma concentrations with each 100 ng/mL increase in Mavacamten concentration lowering FS by 4.9%. Treatment with Mavacamten eliminates SAM in 5/5 subjects, whereas SAM persists in 3/3 subjects treated with vehicle alone. Pressure gradients across the LVOT drop to 11.1±5.0 mmHg with Mavacamten treatment; whereas vehicle treated cats maintain stable LVOT pressure gradients. Mavacamten reduces contractility by decreasing the adenosine triphosphatase activity of the cardiac myosin heavy chain. Chronic administration of Mavacamten suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, and myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice harboring heterozygous human mutations in the myosin heavy chain.|Products are for research use only. Not for human use.|
